Amicus Therapeutics — Q1 2019 Earnings Presentation
24 slides from Amicus Therapeutics's earnings presentation, May 8, 2019
Slide 1: 1Q19 Financial Results Conference Call & Webcast
1Q19 Financial Results Conference Call & Webcast May 8, 2019
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and
Slide 3: 2019 Key Strategic Priorities
Introduction 3 2019 Key Strategic Priorities 1 Nearly double annual revenue for Galafold® (guidance $160M-$180M) Complete enrollment in AT-GAA Pivotal Study (PROPEL) and 2 report additional Phase 1/2 data Report additional 2-year clinical results in CLN6-Batten disease and 3 complete enrollment in o
Slide 4: Galafold (migalastat) Global Launch
Galafold® (migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement
Slide 5: Galafold: Precision Medicine for Fabry Disease Snapshot
Galafold: Precision Medicine for Fabry Disease 5 Galafold Snapshot (as of March 31, 2019) $34.0M $160-180M One of the Most 1Q19 Galafold FY19 Global Revenue Galafold Successful Rare Rev. Guidance Disease Launches Geographic 24 Countries with Expansion in Pricing & 2019 Reimbursement 8 Regulatory 348
Slide 6: Galafold Global Launch Momentum
6 Galafold Global Launch Momentum (as of March 31, 2019) Q1 was very strong with largest number of net new patient adds (150+) and positive momentum across all key commercial metrics . Global: 150+ new patient adds with continued >90% compliance and adherence. Now estimate ~18% global market share o
Slide 7: Galafold Quarterly Performance
Galafold: Precision Medicine for Fabry Disease 7 Galafold Quarterly Performance 1Q19 Revenue of $34.0M Grew 104% Year-over-Year Reflecting Continued Strong Growth in Global Adoption of First Fabry Oral Precision Medicine • 1Q19 in-line with management $34.0M $32.6M expectations • Consistent with Gal
Slide 8: Galafold Success and FY19 Revenue Guidance
Galafold: Precision Medicine for Fabry Disease 8 Galafold Success and FY19 Galafold Revenue Guidance On Track to Nearly DOUBLE Revenue Again and Serve 1,000+ Patients in 2019 $160M-180M Guidance $91.2M $32.6M $36.9M $20.6M $21.3M $5.0M $16.7M FY16 FY17 FY18 FY19
Slide 9: Upside Potential: Total Amenable Patient Population
Galafold: Precision Medicine for Fabry Disease 9 Upside Potential Total Amenable Patient Population (“TAPP”) WORLDWIDE Estimate based on 35% - 50% amenability Diagnosis grows due to newborn screening and patient finding initiatives in U.S. & Japan $1B+ Addressable Market TAPP: 4,700-6,750 Peak Poten
Slide 10: AT-GAA Novel ERT for Pompe Disease
AT-GAA Novel ERT for Pompe Disease “We encourage and embrace constant innovation” - Amicus Belief Statement
Slide 11: PROPEL (ATB200-03) Study Design
AT-GAA for Pompe Disease 11 PROPEL (ATB200-03) Study Design 52-Week Primary Treatment Period Long-Term Extension (Double-Blind) (Open-Label) Participants with AT-GAA Late-Onset Pompe Disease Bi-Weekly ~100 Patients AT-GAA 90 Clinical Sites Worldwide Bi-weekly ERT-Switch Standard of Care ERT-Naïve Bi
Slide 12: AT-GAA: Breakthrough Therapy Designation
AT-GAA for Pompe Disease 12 AT-GAA: Breakthrough Therapy Designation U.S. FDA Granted BTD to AT-GAA in Late-Onset Pompe Disease (LOPD) BTD Criteria • Intended to treat a serious or life threatening disease or condition • Preliminary clinical evidence indicates drug may demonstrate substantial improv
Slide 13: AT-GAA: 2019 Objectives
AT-GAA for Pompe Disease 13 AT-GAA: 2019 Objectives Advance AT-GAA for as Many Patients Worldwide as Quickly as Possible Additional Phase 1/2 Data (up to 24 Months) Breakthrough Therapy Designation Full enrollment of Phase 1/2 Study (Cohorts 1-4) • Full enrollment of PROPEL study (n=100) • Pre
Slide 14: Gene Therapy Pipeline
Gene Therapy Pipeline “We have a duty to obsolete our own technologies” - Amicus Belief Statement
Slide 15: Amicus Pipeline
Amicus Pipeline 15 DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold®(migalastat) monotherapy Fabry Gene Therapy PENN Pompe Franchise AT-GAA (Novel ERT + Chaperone) Pompe Gene Therapy PENN Batten Franchise – Gene Therapies NCH CLN6 Batten Disease Advancing one NC
Slide 16: Amicus Gene Therapy Programs
Amicus Gene Therapy Programs 16 Leading Lysosomal Disorder Gene Therapy Portfolio Multiple Platforms Provide 14 Gene Therapy Programs and R&D Engine for Future Growth Gene Therapy Program Updates Positive initial preclinical data for Pompe gene therapy CLN3 Batten Disease Phase 1/2 Study Enrolling;
Slide 17: Preclinical Pompe Gene Therapy Results
Preclinical Pompe Gene Therapy Results 17 Preclinical Pompe Gene Therapy Results Presented at ASGCT Initial Findings Validate Amicus/Penn Collaboration Combining Amicus-Engineered Transgenes with Penn’s AAV Gene Therapy Technologies Key findings: • Improved cellular uptake and glycogen reduction obs
Slide 18: Milestones
Milestones “We have a duty to obsolete our own technologies” - Amicus Belief Statement
Slide 19: Anticipated Milestones: 2019
Upcoming Milestones 19 Anticipated Milestones: 2019 Well-Positioned to Create Significant Value for Patients and Shareholders in 2019 Galafold: Fabry Disease AT-GAA: Pompe Disease Gene Therapy Programs • FY19 revenue guidance $160M- Additional Phase 1/2 data (21 and 24 • Ongoing CLN3 Batten diseas
Slide 20: Financial Summary Quarter Ended March 31, 2019
Financial Summary Quarter Ended March 31, 2019 “Maximizing Value for Shareholders is the Foundation for Our Future Successes” - Amicus Belief Statement
Slide 21: 1Q19 Select Financial Results
Financial Summary 21 1Q19 Select Financial Results 1Q19 Revenue was $34.0M (+104% vs. 1Q18). Includes YoY Operational Revenue Growth Measured at Constant Currency Exchange Rates of 114.9%, Offset by Negative Currency Impact of $1.8M, or 11.0%. Mar. 31, 2019 (in thousands, except per share data) Mar.
Slide 22: Financial Summary and Guidance
Financial Summary 22 Financial Summary and Guidance Strong Balance Sheet with $435M+ Cash at 3/31/19- Cash Runway into 2021 FINANCIAL POSITION March 31, 2019 Cash ~$438M Cash Runway Into at least mid-2021 CAPITALIZATION Shares Outstanding 230,180,714 FINANCIAL GUIDANCE Projected YE 2019 Cash Balance
Slide 23: Closing: Impacting Lives
Closing 23 Impacting Lives >350 Patients* | ~$36M Global Sales >700 Patients* | ~$91M1 Global Sales 5,000 Patients* | $1B Global Sales YE17 YE18 2023 *Clinical & commercial, all figures approximate 1Preliminary unaudited
Slide 24: Thank You
Thank You “Our passion for making a difference unites us” -Amicus Belief Statement